Compare WASH & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WASH | CTMX |
|---|---|---|
| Founded | 1800 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.9M | 642.2M |
| IPO Year | 1994 | 2015 |
| Metric | WASH | CTMX |
|---|---|---|
| Price | $35.85 | $3.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $30.25 | $12.10 |
| AVG Volume (30 Days) | 192.3K | ★ 5.3M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | ★ 266.26 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $229,048,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.19 | $7.61 |
| P/E Ratio | $53.95 | ★ $22.58 |
| Revenue Growth | ★ 127.57 | N/A |
| 52 Week Low | $25.23 | $1.72 |
| 52 Week High | $37.08 | $8.21 |
| Indicator | WASH | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 57.67 |
| Support Level | $31.53 | $3.40 |
| Resistance Level | $36.79 | $3.90 |
| Average True Range (ATR) | 0.78 | 0.25 |
| MACD | -0.15 | 0.08 |
| Stochastic Oscillator | 55.13 | 75.23 |
Washington Trust Bancorp Inc through its subsidiaries, offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, wealth management, and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services, including services as trustee, personal representative, custodian, and guardian, and settlement of decedents' estates.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.